(Q34701702)

4 August 2017

title

Phase 0 clinical chemoprevention trial of the Akt inhibitor SR13668 (English)

1 reference

4 August 2017

17

Paul J Limburg

1 reference

4 August 2017

Joel M Reid

1

1 reference

4 August 2017

Chad A Walden

2

1 reference

4 August 2017

Rui Qin

3

1 reference

4 August 2017

Katie L Allen Ziegler

4

1 reference

4 August 2017

John L Haslam

5

1 reference

4 August 2017

Roger A Rajewski

6

1 reference

4 August 2017

Roger Warndahl

7

1 reference

4 August 2017

Cindy L Fitting

8

1 reference

4 August 2017

Daniel Boring

9

1 reference

4 August 2017

Eva Szabo

10

1 reference

4 August 2017

James Crowell

11

1 reference

4 August 2017

Marjorie Perloff

12

1 reference

4 August 2017

Ling Jong

13

1 reference

4 August 2017

Brent A Bauer

14

1 reference

4 August 2017

Sumithra J Mandrekar

15

1 reference

4 August 2017

Matthew M Ames

16

1 reference

4 August 2017

Cancer Prevention Network

18

1 reference

4 August 2017

publication date

1 March 2011

1 reference

Cancer Prevention Research

4 August 2017

published in

1 reference

4 August 2017

volume

4

1 reference

4 August 2017

issue

3

1 reference

4 August 2017

page(s)

347-353

1 reference

Improved oral bioavailability in rats of SR13668, a novel anti-cancer agent

4 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3061470

The statistics of phase 0 trials

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3061470

Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3061470

Designing phase 0 cancer clinical trials

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3061470

Enhancing intestinal drug solubilisation using lipid-based delivery systems.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3061470

Computer-aided rational drug design: a novel agent (SR13668) designed to mimic the unique anticancer mechanisms of dietary indole-3-carbinol to block Akt signaling

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3061470

Inhibition of nuclear translocation of nuclear factor-{kappa}B contributes to 3,3'-diindolylmethane-induced apoptosis in breast cancer cells.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3061470

Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3061470

A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3061470

Pharmacokinetics and enhanced bioavailability of candidate cancer preventative agent, SR13668 in dogs and monkeys

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3061470

Impact of economic, regulatory, and patent policies on innovation in cancer chemoprevention

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3061470

Evaluation of chemopreventive agents for genotoxic activity.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3061470

Compressing drug development timelines in oncology using phase '0' trials.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3061470

Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3061470

Akt inactivation is a key event in indole-3-carbinol-induced apoptosis in PC-3 cells.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3061470

AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3061470

10.1158/1940-6207.CAPR-10-0313

26 October 2018

Identifiers

DOI

1 reference

4 August 2017

1 reference

4 August 2017

1 reference